Microenvironment Remodeling. The third pillar aims to reverse the non-autonomous aspects of MDR by using nanomedicines to reprogram the tumor immune landscape, converting immunologically cold tumors into hot, therapy-responsive ones
Longer follow-up in the ongoing SURPASS-CVOT trial, comparing tirzepatide with dulaglutide, is needed to confirm if there is a cardiovascular benefit with tirzepatide, as seen with liraglutide, dulaglutide and semaglutide
S., & Naidu, M
Supports the reduced/oxidized glutathione discussion, including GSSG conversion back to GSH by glutathione reductase, GSHs role in detoxification, vitamin E regeneration, redox signaling, and antioxidant defense
Most patients see significant improvement within months by following dietary advice and medical guidance